Business
Cryoport Announces Proposed Public Offering of Common Stock
NASHVILLE, Tenn., Jan. 19, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply
About this update from Cryoport, Inc.
[{"type":"text","content":"NASHVILLE, Tenn., Jan. 19, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) (\"Cryoport\" or the \"Company\"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that it intends to offer $200 million of shares of common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Cryoport also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price. All of the shares in the offering are to be sold by Cryoport.\n\n \n \n \n \n \n \n\n \nThe Company expects to use the net proceeds from the offering of the shares for general corporate purposes, which may include working capital, inventory development, global infrastructure buildout and facilities expansion, sales and marketing.\nMorgan Stanley, Jefferies, SVB Leerink, and UBS Investment Bank are acting as joint book-running managers for the offering. \nThe public offering will be made pursuant to an automatic shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (the \"SEC\") and automatically became effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC's website located at http://www.sec.gov or may be obtained from Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Jefferies, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388 or by email at [email protected]; SVB Leerink, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525, ext. 6132 or by email at [email protected]; or UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, by telephone at (888) 827-7275 or by email at [email protected]. \nThis press release shall not constitute an offer to sell or th...